Form 4: Immunovant's Chief Medical Officer Sells Shares to Cover Tax Obligations

William L. Macias, Chief Medical Officer of Immunovant, Inc., sold shares of common stock to cover tax withholding obligations related to the vesting of restricted stock units.

Summary

• On July 17, 2024, William L. Macias, the Chief Medical Officer of Immunovant, Inc., sold shares of the company's common stock.
• The sales were executed to cover tax withholding obligations associated with the vesting of restricted stock units (RSUs).
• A total of 2,362 shares were sold at a weighted average price of $29.64, 147 shares were sold at a weighted average price of $30.55, 504 shares were sold at a weighted average price of $29.64 and 31 shares were sold at a weighted average price of $30.55.
• These sales were mandated by Immunovant's policy requiring tax obligations to be funded through 'sell to cover' transactions and do not represent discretionary sales by Mr. Macias.
• Following these transactions, Mr. Macias still beneficially owns 371,359 shares of Immunovant common stock.

Sentiment

Score: 5

Explanation: This is a routine transaction related to executive compensation and tax obligations, and does not reflect a change in the company's fundamentals or outlook. Therefore, the sentiment is neutral.

Industry Context

Executive share sales to cover tax obligations upon RSU vesting are a common practice in publicly traded companies. This transaction is not indicative of a change in the company's outlook or the executive's confidence in the company.

Comparison to Industry Standards

• Executive compensation packages often include RSUs, which vest over time and are subject to income tax upon vesting.
• Companies like Amgen, Regeneron, and Biogen also have executives who periodically sell shares to cover tax obligations related to RSU vesting.
• The 'sell to cover' practice is a standard method for managing these tax liabilities, ensuring executives can meet their obligations without needing to use personal funds.

Stakeholder Impact

• The sale of shares by the Chief Medical Officer may have a minor, temporary impact on the stock price due to the increased supply of shares in the market.
• However, since the sale is for tax obligations and not a discretionary sale, it is unlikely to have a significant long-term impact on shareholder value.

Key Dates